(Q38192045)

30 August 2017

1 reference

title

Primary biliary cirrhosis in adults (English)

1 reference

primary biliary cholangitis

30 August 2017

main subject

0 references

author name string

Njideka Momah

series ordinal

1

1 reference

30 August 2017

Keith D Lindor

series ordinal

2

1 reference

30 August 2017

publication date

3 March 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

published in

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

427-433

1 reference

The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Epidemiology and natural history of primary biliary cirrhosis in a US community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

The geographical distribution of primary biliary cirrhosis in a well-defined cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Transplantation trends in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Prognosis in primary biliary cirrhosis: model for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Anti-sp100 antibodies in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

The PPARalpha-leukotriene B4 pathway to inflammation control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Identification of a nuclear receptor that is activated by farnesol metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.888950

10.1586/17474124.2014.888950

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference